Trials / Completed
CompletedNCT01759264
An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)
An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 101 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this observational study was to assess changes in fecal calprotectin levels and its suitability as a monitoring tool in participants with moderate-to-severe Crohn's Disease who were treated with adalimumab.
Conditions
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2013-01-03
- Last updated
- 2015-07-08
- Results posted
- 2015-07-08
Source: ClinicalTrials.gov record NCT01759264. Inclusion in this directory is not an endorsement.